As GLP-1 medications such as Ozempic, Mounjaro and Wegovy rise in popularity, so do concerns over their side effects.

GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.

The big pharma sector is one that’s generally fallen out of favor for many investors over the past few decades, as large ...

Conagra and General Mills are among the food companies offering special options for people on GLP-1 drugs, but the products ...

In addition, the Company closed its previously announced concurrent private placement with funds affiliated with Leavitt Equity Partners for the purchase and sale of 267,686 shares of common stock and ...

Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. See why I rate ...

No. 2 / 2025Zealand Pharma Announces Financial Results for the Full Year 2024A transformational year with significant ...

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...

Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.